fentanyl has been researched along with Dyspnea in 49 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Dyspnea: Difficult or labored breathing.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A randomized, double-blind, placebo-controlled crossover comparison of 100 mcg nebulized fentanyl vs placebo on dyspnea intensity and inspiratory neural drive (IND) during constant work rate (CWR) cycle exercise was performed in 21 ILD patients." | 9.34 | Inspiratory neural drive and dyspnea in interstitial lung disease: Effect of inhaled fentanyl. ( Ibrahim-Masthan, M; Ja, N; James, MD; Milne, KM; Moran-Mendoza, O; O'Donnell, DE; Phillips, DB; Scheeren, RE, 2020) |
| "The optimal dose of fentanyl sublingual spray (FSS) for exertional dyspnea has not been determined." | 9.30 | Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial. ( Azhar, A; Bruera, E; Dalal, S; Dev, R; Driver, L; Haider, A; Hernandez, F; Hui, D; Kilgore, K; Larsson, L; Liu, D; Naberhuis, J; Reddy, A; Reddy, S; Virgilio, A, 2019) |
| "We conducted a pilot study to examine the effect of prophylactic fentanyl buccal tablet (FBT) on exercise-induced dyspnea." | 9.24 | Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. ( Balachandran, DD; Bruera, E; Frisbee-Hume, S; Hui, D; Kilgore, K; Liu, D; Park, M, 2017) |
| "In this pilot study, we examined the effect of prophylactic fentanyl pectin nasal spray (FPNS) on exercise-induced dyspnea, physiologic function, and adverse events." | 9.22 | Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. ( Bruera, E; Hui, D; Kilgore, K; Liu, D; Park, M; Williams, J, 2016) |
| "To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness." | 9.22 | EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. ( Alt-Epping, B; Cornely, OA; Gärtner, J; Hein, R; Hellmich, M; Kloke, M; Nauck, F; Piel, M; Simon, ST; Voltz, R, 2016) |
| "To evaluate the efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of dyspnea on exertion in patients with advanced cancer." | 9.20 | A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. ( Bruera, E; Correas, MÁ; Moralo, MJ; Pinna, MÁ; Vargas, RM, 2015) |
| "Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate." | 9.19 | Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. ( Bruera, E; Chisholm, G; Frisbee-Hume, S; Hui, D; Morgado, M; Reddy, S; Xu, A, 2014) |
| "We performed a systematic review to evaluate the current evidence for the use of fentanyl for the relief of breathlessness." | 8.89 | Fentanyl for the relief of refractory breathlessness: a systematic review. ( Gaertner, J; Köskeroglu, P; Simon, ST; Voltz, R, 2013) |
| "Nebulized fentanyl is well established for analgesia but its use for dyspnea requires further investigation." | 7.96 | Nebulized Fentanyl for Dyspnea: A Retrospective Chart Review. ( Cain, J; Coyne, PJ; Dulin, JD; Higgins, EA; Miller, MM; Overstreet, AN; Vaughan, L; Young, AM, 2020) |
| "In this pilot study, the preadministration of intranasal fentanyl prior to activity in palliative, end-stage hospitalized heart failure patients, safely reduced tachypnea, and the feeling of shortness of breath." | 7.91 | The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study. ( Malik, A; Pedersen, A; Pilkey, J; Tam, JW; Wong, J, 2019) |
| "This exploratory study shows that IV Fentanyl can alleviate dyspnea in some patients but is an example of the difficulties conducting dyspnea research." | 7.83 | Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea. ( Pang, GS; Qu, LM; Tan, YY; Yee, AC, 2016) |
| " We treated a 50s female with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for NSCLC in whom the optimal dosages of transdermal fentanyl (Durotep Patch) were determined by titration with fentanyl injection, and oxycodone hydrochloride (OxyContin) in a short period." | 7.76 | [Successful management of a patient with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for non-small cell lung cancer (NSCLC) in whom optimal dosages of transdermal fentanyl were determined by titration with fentanyl i ( Eguchi, K; Gika, M; Inoue, Y; Izawa, N; Nakayama, M; Takeuchi, K, 2010) |
| "To evaluate the efficacy and safety of oral transmucosal fentanyl citrate (OTFC) in terminally ill patients experiencing dyspnea." | 7.74 | Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. ( Gauna, AA; Kang, SK; Swatko, ER; Triano, ML; Vanston, VJ, 2008) |
| "Episodic breathlessness is a distressing and difficult to treat symptom because of its short duration." | 7.01 | Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases. ( Allan, S; Bridge, R; Hewitt, D; Iupati, S, 2021) |
| " Low dosed opioids have been investigated for refractory dyspnea in COPD and other life-limiting conditions, and some positive effects were demonstrated." | 6.72 | Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD). ( de Hosson, SM; Heller-Baan, R; Kerstjens, HAM; Lam-Wong, WY; Mooren, KJM; Peters, L; Pool, K; van Beurden-Moeskops, WJC; van den Berg, JK; van Dijk, M, 2021) |
| "Fentanyl is an appropriate drug because of its fast onset and short duration of action." | 6.45 | [Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report]. ( Sitte, T, 2009) |
| " The purpose of this study is to investigate the efficacy of nebulized fentanyl citrate on dyspnea, cough, and throat pain in patients with COVID-19 and evaluate the safety with any potential adverse events." | 5.51 | Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial). ( Abujaber, AA; Al-Assaf, AA; Khatib, MY; Mohamed, AS; Nashwan, AJ; Shaikh, N; Tharayil, AGM; Wraidat, MAA, 2022) |
| " A randomized, double-blind, placebo-controlled crossover comparison of 100 mcg nebulized fentanyl vs placebo on dyspnea intensity and inspiratory neural drive (IND) during constant work rate (CWR) cycle exercise was performed in 21 ILD patients." | 5.34 | Inspiratory neural drive and dyspnea in interstitial lung disease: Effect of inhaled fentanyl. ( Ibrahim-Masthan, M; Ja, N; James, MD; Milne, KM; Moran-Mendoza, O; O'Donnell, DE; Phillips, DB; Scheeren, RE, 2020) |
| "The optimal dose of fentanyl sublingual spray (FSS) for exertional dyspnea has not been determined." | 5.30 | Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial. ( Azhar, A; Bruera, E; Dalal, S; Dev, R; Driver, L; Haider, A; Hernandez, F; Hui, D; Kilgore, K; Larsson, L; Liu, D; Naberhuis, J; Reddy, A; Reddy, S; Virgilio, A, 2019) |
| "We conducted a pilot study to examine the effect of prophylactic fentanyl buccal tablet (FBT) on exercise-induced dyspnea." | 5.24 | Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. ( Balachandran, DD; Bruera, E; Frisbee-Hume, S; Hui, D; Kilgore, K; Liu, D; Park, M, 2017) |
| "In this pilot study, we examined the effect of prophylactic fentanyl pectin nasal spray (FPNS) on exercise-induced dyspnea, physiologic function, and adverse events." | 5.22 | Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. ( Bruera, E; Hui, D; Kilgore, K; Liu, D; Park, M; Williams, J, 2016) |
| "To determine time to onset, efficacy, feasibility, and safety of transmucosal fentanyl in comparison to immediate-release morphine for the relief of episodic breathlessness." | 5.22 | EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. ( Alt-Epping, B; Cornely, OA; Gärtner, J; Hein, R; Hellmich, M; Kloke, M; Nauck, F; Piel, M; Simon, ST; Voltz, R, 2016) |
| "To evaluate the efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of dyspnea on exertion in patients with advanced cancer." | 5.20 | A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. ( Bruera, E; Correas, MÁ; Moralo, MJ; Pinna, MÁ; Vargas, RM, 2015) |
| "Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate." | 5.19 | Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. ( Bruera, E; Chisholm, G; Frisbee-Hume, S; Hui, D; Morgado, M; Reddy, S; Xu, A, 2014) |
| "We performed a systematic review to evaluate the current evidence for the use of fentanyl for the relief of breathlessness." | 4.89 | Fentanyl for the relief of refractory breathlessness: a systematic review. ( Gaertner, J; Köskeroglu, P; Simon, ST; Voltz, R, 2013) |
| "Nebulized fentanyl is well established for analgesia but its use for dyspnea requires further investigation." | 3.96 | Nebulized Fentanyl for Dyspnea: A Retrospective Chart Review. ( Cain, J; Coyne, PJ; Dulin, JD; Higgins, EA; Miller, MM; Overstreet, AN; Vaughan, L; Young, AM, 2020) |
| "In this pilot study, the preadministration of intranasal fentanyl prior to activity in palliative, end-stage hospitalized heart failure patients, safely reduced tachypnea, and the feeling of shortness of breath." | 3.91 | The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study. ( Malik, A; Pedersen, A; Pilkey, J; Tam, JW; Wong, J, 2019) |
| "Among Japanese palliative care physicians, using oxycodone for cancer dyspnea was relatively popular practice, whereas fentanyl was not." | 3.91 | The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians. ( Matsuda, Y; Matsunuma, R; Mori, M; Suzuki, K; Watanabe, H; Yamaguchi, T, 2019) |
| "This exploratory study shows that IV Fentanyl can alleviate dyspnea in some patients but is an example of the difficulties conducting dyspnea research." | 3.83 | Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea. ( Pang, GS; Qu, LM; Tan, YY; Yee, AC, 2016) |
| " We treated a 50s female with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for NSCLC in whom the optimal dosages of transdermal fentanyl (Durotep Patch) were determined by titration with fentanyl injection, and oxycodone hydrochloride (OxyContin) in a short period." | 3.76 | [Successful management of a patient with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for non-small cell lung cancer (NSCLC) in whom optimal dosages of transdermal fentanyl were determined by titration with fentanyl i ( Eguchi, K; Gika, M; Inoue, Y; Izawa, N; Nakayama, M; Takeuchi, K, 2010) |
| "To evaluate the efficacy and safety of oral transmucosal fentanyl citrate (OTFC) in terminally ill patients experiencing dyspnea." | 3.74 | Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series. ( Gauna, AA; Kang, SK; Swatko, ER; Triano, ML; Vanston, VJ, 2008) |
| "Episodic breathlessness is a distressing and difficult to treat symptom because of its short duration." | 3.01 | Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases. ( Allan, S; Bridge, R; Hewitt, D; Iupati, S, 2021) |
| " Low dosed opioids have been investigated for refractory dyspnea in COPD and other life-limiting conditions, and some positive effects were demonstrated." | 2.72 | Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD). ( de Hosson, SM; Heller-Baan, R; Kerstjens, HAM; Lam-Wong, WY; Mooren, KJM; Peters, L; Pool, K; van Beurden-Moeskops, WJC; van den Berg, JK; van Dijk, M, 2021) |
| "Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB." | 2.58 | Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management. ( Mercadante, S, 2018) |
| "Inhaled morphine improved breathlessness in chronic obstructive pulmonary disease patients." | 2.50 | Inhaled nebulized and intranasal opioids for the relief of breathlessness. ( Bausewein, C; Simon, ST, 2014) |
| "Fentanyl is an appropriate drug because of its fast onset and short duration of action." | 2.45 | [Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report]. ( Sitte, T, 2009) |
| "Pneumomediastinum is a rare complication of substance use, likely due to a Valsalva maneuver after drug inhalation." | 1.72 | Tension pneumomediastinum from opioid inhalation. ( Chicotka, S; Coffey, C; Hryniewicki, AT; Nene, RV; Odish, MF; Roderick, E; Thistlewaite, PA; Vazquez, MH, 2022) |
| "Fentanyl efficacy was not statistically related to age, gender, cancer type, previous opioid treatment, steroid and midazolam doses and PPS." | 1.51 | Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients. ( Benítez-Rosario, MA; González-Dávila, E; Rosa-González, I; Sanz, E, 2019) |
| "Dyspnea is a prognostic factor that affects the quality of life of terminal cancer patients, and many reports have described opioid treatment for dyspnea alleviation." | 1.43 | Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review. ( Hayakawa, T; Maeda, T, 2016) |
| "Supraventricular tachycardia is uncommon in pregnancy." | 1.40 | Management of labour and delivery in a woman with refractory supraventricular tachycardia. ( Dennis, AT; Gerstman, MD, 2014) |
| "This syndrome is relatively uncommon and accompanies dyspnea and hypoxemia on changing to a sitting or standing from recumbent position." | 1.32 | [Anesthetic management for a patient with platypnea-orthodeoxia syndrome]. ( Kawamoto, K; Terasaki, H; Yoshitake, A, 2004) |
| "Subcutaneous emphysema was observed to the cervical zone after surgery but discharge was not delayed." | 1.31 | [Subarachnoid anesthesia in the repair of urinary stress incontinence using a Burch-type colposuspension by means of extraperitoneal laparoscopy]. ( de Santos, P; Faulí, A; Gomar, C; Martínez, S; Pérez, J; Plaza, A; Vanrell, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 16 (32.65) | 29.6817 |
| 2010's | 26 (53.06) | 24.3611 |
| 2020's | 6 (12.24) | 2.80 |
| Authors | Studies |
|---|---|
| van Dijk, M | 1 |
| Mooren, KJM | 1 |
| van den Berg, JK | 1 |
| van Beurden-Moeskops, WJC | 1 |
| Heller-Baan, R | 1 |
| de Hosson, SM | 1 |
| Lam-Wong, WY | 1 |
| Peters, L | 1 |
| Pool, K | 1 |
| Kerstjens, HAM | 1 |
| Nene, RV | 1 |
| Hryniewicki, AT | 1 |
| Roderick, E | 1 |
| Chicotka, S | 1 |
| Vazquez, MH | 1 |
| Thistlewaite, PA | 1 |
| Coffey, C | 1 |
| Odish, MF | 1 |
| Shaikh, N | 1 |
| Khatib, MY | 1 |
| Wraidat, MAA | 1 |
| Mohamed, AS | 1 |
| Al-Assaf, AA | 1 |
| Tharayil, AGM | 1 |
| Abujaber, AA | 1 |
| Nashwan, AJ | 1 |
| Higgins, EA | 1 |
| Young, AM | 1 |
| Cain, J | 1 |
| Dulin, JD | 1 |
| Miller, MM | 1 |
| Overstreet, AN | 1 |
| Vaughan, L | 1 |
| Coyne, PJ | 2 |
| Milne, KM | 1 |
| Ibrahim-Masthan, M | 1 |
| Scheeren, RE | 1 |
| James, MD | 1 |
| Phillips, DB | 1 |
| Moran-Mendoza, O | 1 |
| Ja, N | 1 |
| O'Donnell, DE | 1 |
| Iupati, S | 1 |
| Bridge, R | 1 |
| Allan, S | 1 |
| Hewitt, D | 1 |
| Hui, D | 6 |
| Kilgore, K | 3 |
| Frisbee-Hume, S | 2 |
| Park, M | 2 |
| Liu, D | 3 |
| Balachandran, DD | 1 |
| Bruera, E | 7 |
| Mercadante, S | 1 |
| Pilkey, J | 1 |
| Pedersen, A | 1 |
| Tam, JW | 1 |
| Malik, A | 1 |
| Wong, J | 1 |
| Benítez-Rosario, MA | 2 |
| Rosa-González, I | 1 |
| González-Dávila, E | 1 |
| Sanz, E | 1 |
| Yamaguchi, T | 1 |
| Matsunuma, R | 1 |
| Suzuki, K | 1 |
| Matsuda, Y | 1 |
| Mori, M | 1 |
| Watanabe, H | 1 |
| Hernandez, F | 1 |
| Larsson, L | 1 |
| Naberhuis, J | 1 |
| Virgilio, A | 1 |
| Reddy, S | 2 |
| Reddy, A | 1 |
| Dalal, S | 1 |
| Haider, A | 1 |
| Driver, L | 1 |
| Azhar, A | 1 |
| Dev, R | 1 |
| Kako, J | 1 |
| Kajiwara, K | 1 |
| Noto, H | 1 |
| Oosono, Y | 1 |
| Kobayashi, M | 1 |
| Simon, ST | 3 |
| Köskeroglu, P | 1 |
| Gaertner, J | 1 |
| Voltz, R | 2 |
| Xu, A | 1 |
| Chisholm, G | 1 |
| Morgado, M | 1 |
| Pinna, MÁ | 1 |
| Moralo, MJ | 1 |
| Correas, MÁ | 2 |
| Vargas, RM | 1 |
| Dennis, AT | 1 |
| Gerstman, MD | 1 |
| Cuervo Pinna, MÁ | 2 |
| Sanz Rubiales, Á | 1 |
| del Valle, ML | 1 |
| Bausewein, C | 2 |
| Pang, GS | 1 |
| Qu, LM | 1 |
| Tan, YY | 1 |
| Yee, AC | 1 |
| Kotrach, HG | 1 |
| Bourbeau, J | 1 |
| Jensen, D | 1 |
| Maeda, T | 1 |
| Hayakawa, T | 1 |
| Williams, J | 1 |
| Kloke, M | 1 |
| Alt-Epping, B | 1 |
| Gärtner, J | 1 |
| Hellmich, M | 1 |
| Hein, R | 1 |
| Piel, M | 1 |
| Cornely, OA | 1 |
| Nauck, F | 1 |
| Wahler, RG | 1 |
| Smith, DB | 1 |
| Mulcahy, KB | 1 |
| Mota Vargas, R | 1 |
| Redondo Moralo, MJ | 1 |
| Sitte, T | 2 |
| Bauer, MD | 1 |
| Clark-Price, SC | 1 |
| McFadden, MS | 1 |
| Smith, TJ | 2 |
| Coyne, P | 1 |
| French, W | 1 |
| Ramakrishnan, V | 1 |
| Corrigan, P | 1 |
| Gika, M | 1 |
| Eguchi, K | 1 |
| Inoue, Y | 1 |
| Izawa, N | 1 |
| Takeuchi, K | 1 |
| Nakayama, M | 1 |
| Tajitsu, T | 1 |
| Matsuura, S | 1 |
| Kawagoe, K | 1 |
| Dang, D | 1 |
| Robinson, PC | 1 |
| Winnicki, S | 1 |
| Jersmann, HP | 1 |
| Shlamovitz, GZ | 1 |
| Elsayem, A | 1 |
| Todd, KH | 1 |
| Rivero, C | 1 |
| Cerizola, M | 1 |
| Kohn, E | 1 |
| Riva, J | 1 |
| Pastor Tomás, EM | 1 |
| Arribas del Amo, D | 1 |
| Gómez Gómez, R | 1 |
| Córdoba Díaz de Laspra, E | 1 |
| Saiz Gormaz, J | 1 |
| Kawamoto, K | 1 |
| Yoshitake, A | 1 |
| Terasaki, H | 1 |
| Schultheis, CP | 1 |
| Kimoto, M | 1 |
| Murao, K | 1 |
| Shirane, A | 1 |
| Sakamoto, S | 1 |
| Yamada, M | 1 |
| Nakao, S | 1 |
| Shingu, K | 1 |
| Martin, AS | 1 |
| Feria, M | 1 |
| Zylicz, Z | 1 |
| van Rijn-van der Plaat, LL | 1 |
| Gauna, AA | 1 |
| Kang, SK | 1 |
| Triano, ML | 1 |
| Swatko, ER | 1 |
| Vanston, VJ | 1 |
| Glass, E | 1 |
| D'Olimpio, J | 1 |
| Viswanathan, R | 1 |
| de Santos, P | 1 |
| Plaza, A | 1 |
| Faulí, A | 1 |
| Pérez, J | 1 |
| Martínez, S | 1 |
| Vanrell, J | 1 |
| Gomar, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Morphine or Fentanyl for Refractory Dyspnea in COPD[NCT03834363] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-11-15 | Recruiting | ||
| Pulmonary Gas Exchange and Neuro-sensory Abnormalities in Patients With Idiopathic Pulmonary Fibrosis and Mild Mechanical Restriction. Implications for Dyspnea and Exercise Intolerance[NCT05052229] | Early Phase 1 | 40 participants (Anticipated) | Interventional | 2022-04-21 | Recruiting | ||
| Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized Controlled Trial[NCT01515566] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Effects of Inhaled Fentanyl Citrate on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction[NCT01853449] | Early Phase 1 | 14 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea[NCT01832402] | Phase 2 | 35 participants (Actual) | Interventional | 2013-06-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Retention rate is defined as the percentage of subjects able to complete the study. (NCT01515566)
Timeframe: Baseline to study completion, up to 100 minutes.
| Intervention | percentage of participants (Number) |
|---|---|
| Fentanyl | 100 |
| Placebo | 100 |
Ambulatory patients with breakthrough dyspnea performed a baseline 6 minute walk test (6MWT), and then received either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. The change in walk distance was documented between the first and second 6MWT. (NCT01515566)
Timeframe: Baseline 6 minute walk test (6MWT) to second 6MWT, up to 100 minutes for study participation.
| Intervention | feet (Mean) | |
|---|---|---|
| Walk Distance (Baseline Walk Test) | Walk Distance (Second Walk Test) | |
| Fentanyl | 397.7 | 434.9 |
| Placebo | 399 | 417.9 |
"Participants receive either Fentanyl subcutaneous (SQ) 15 minutes before walking test, or Placebo (SQ) 15 minutes before walking test. During the study, trained research staff perform study assessments and monitor participant carefully throughout the study period. Six-minute walk tests were carried out following guidelines from the American Thoracic Society. The intensity of dyspnea at 0, 1, 2, 3, 4, 5 and 6 minute of each walk test were assessed using a validated numeric rating scale (NRS) ranging from 0 (no shortness of breath) to 10 (worst possible shortness of breath) and every 5 minutes during the rest period." (NCT01515566)
Timeframe: Baseline to 100 minutes for study participation.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Dyspnea at 0 minutes (Baseline walk test) | Dyspnea at 6 minutes (Baseline walk test) | Dyspnea at 0 minutes (Second walk test) | Dyspnea at 6 minutes (Second walk test) | |
| Fentanyl | 2 | 6 | 1 | 4 |
| Placebo | 3 | 7 | 2 | 5 |
"Assessed dyspnea using the modified Dyspnea Borg Scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of modified Dyspnea Borg scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests." (NCT01832402)
Timeframe: 1.5 to 2 hours on a Single visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Mean difference between 1st and 2nd walk tests | Mean difference between 1st and 3rd walk tests | |
| Controlled Group (Placebo) | -1.7 | -2.4 |
| Intervention Group (Fentanyl Pectin Nasal Spray) | -1.8 | -1.7 |
"Our primary outcome was dyspnea intensity now using a dyspnea numeric rating scale that ranges from 0 (no shortness of breath) to 10 (worst possible shortness of breath). Measured the mean difference of dyspnea numeric rating scale between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests. 6 minute walk tests were carried out following guidelines from the American Thoracic Society." (NCT01832402)
Timeframe: 1.5 to 2 hours on a Single visit
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Mean difference between 1st and 2nd walk tests | Mean difference between 1st and 3rd walk tests | |
| Controlled Group (Placebo) | -1.7 | -2.5 |
| Intervention Group (Fentanyl Pectin Nasal Spray) | -2.0 | -2.3 |
Compared the mean difference of distance between the first and second 6 Minute Walk Tests and between the first and third 6 Minute Walk Tests. (NCT01832402)
Timeframe: 1.5 to 2 hours on a Single visit
| Intervention | meters (Mean) | |
|---|---|---|
| Mean difference between 1st and 2nd walk tests | Mean difference between 1st and 3rd walk tests | |
| Control Group (Placebo) | 16.3 | 14.6 |
| Interventional Group (Fentanyl Pectin Nasal Spray) | 23.8 | 23.3 |
6 reviews available for fentanyl and Dyspnea
| Article | Year |
|---|---|
Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD).
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Fentanyl; Health | 2021 |
Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management.
Topics: Analgesics, Opioid; Breakthrough Pain; Dyspnea; Fentanyl; Humans; Morphine; Neoplasms; Pain Manageme | 2018 |
Fentanyl for the relief of refractory breathlessness: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Drug-Related Side E | 2013 |
Inhaled nebulized and intranasal opioids for the relief of breathlessness.
Topics: Administration, Inhalation; Administration, Intranasal; Analgesics, Opioid; Dyspnea; Fentanyl; Human | 2014 |
[Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report].
Topics: Acute Disease; Administration, Cutaneous; Administration, Intranasal; Aged, 80 and over; Ambulatory | 2009 |
Contemporary drug therapy in palliative care: new directions.
Topics: Adrenal Cortex Hormones; Analgesics; Anorexia; Antiemetics; Antitussive Agents; Cachexia; Cough; Dru | 2001 |
12 trials available for fentanyl and Dyspnea
| Article | Year |
|---|---|
Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial).
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Analgesics, Opioid; Clinical Trials, Phase III | 2022 |
Inspiratory neural drive and dyspnea in interstitial lung disease: Effect of inhaled fentanyl.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Analgesics, Opioid; Cross-Over Studies; Diaphra | 2020 |
Intranasal Fentanyl Versus Placebo for Treatment of Episodic Breathlessness in Hospice Patients With Advanced Nonmalignant Diseases.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Hospices; Humans; Neoplasms | 2021 |
Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Administration, Buccal; Adult; Aged; Analgesics, Opioid; Comorbidity; Double-Blind Method; Dyspnea; | 2017 |
Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Doubl | 2019 |
Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.
Topics: Adult; Aged; Analgesics, Opioid; Double-Blind Method; Dyspnea; Exercise; Exercise Test; Fatigue; Fea | 2014 |
A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer.
Topics: Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Female; Fe | 2015 |
Does nebulized fentanyl relieve dyspnea during exercise in healthy man?
Topics: Administration, Inhalation; Adult; Analgesics, Opioid; Bicycling; Cross-Over Studies; Double-Blind M | 2015 |
Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.
Topics: Administration, Intranasal; Analgesics, Opioid; Double-Blind Method; Dyspnea; Exercise; Female; Fent | 2016 |
EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial.
Topics: Administration, Buccal; Analgesics, Opioid; Cross-Over Studies; Disease Progression; Dyspnea; Feasib | 2016 |
Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Female; Fentanyl; Health Status Indicators; Humans | 2009 |
Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea.
Topics: Administration, Inhalation; Analgesics, Opioid; Dyspnea; Female; Fentanyl; Humans; Male; Middle Aged | 2002 |
31 other studies available for fentanyl and Dyspnea
| Article | Year |
|---|---|
Tension pneumomediastinum from opioid inhalation.
Topics: Administration, Inhalation; Adult; Dyspnea; Fentanyl; Heroin Dependence; Humans; Male; Mediastinal E | 2022 |
Nebulized Fentanyl for Dyspnea: A Retrospective Chart Review.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Dyspnea; Female; Fen | 2020 |
The Use of Intranasal Fentanyl for the Palliation of Incident Dyspnea in Advanced Congestive Heart Failure: A Pilot Study.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; Dyspnea; Female; Fentanyl; | 2019 |
Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Analgesics, | 2019 |
The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians.
Topics: Analgesics, Opioid; Dyspnea; Fentanyl; Humans; Japan; Morphine; Neoplasms; Oxycodone; Palliative Car | 2019 |
Authors' Response to: Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Humans; Neoplasms | 2019 |
Response to "Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial".
Topics: Analgesics, Opioid; Double-Blind Method; Dyspnea; Fentanyl; Humans; Neoplasms | 2019 |
Management of labour and delivery in a woman with refractory supraventricular tachycardia.
Topics: Adult; Amides; Amnion; Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthesia, Epidural; Anes | 2014 |
A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer.
Topics: Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Fentanyl; Humans; Male; Patient Sa | 2014 |
Placebo-controlled feasibility randomized trial?
Topics: Analgesics, Opioid; Dyspnea; Exercise; Fentanyl; Humans; Walking | 2014 |
The essential role of feasibility studies in supportive care: reply to Sanz Rubiales and del Valle.
Topics: Analgesics, Opioid; Dyspnea; Exercise; Fentanyl; Humans; Walking | 2014 |
Intravenous Fentanyl for Dyspnea at the End of Life: Lessons for Future Research in Dyspnea.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anxiety; Dyspnea; Female; Fentanyl; Humans; Infusions, | 2016 |
Combined Effect of Opioids and Corticosteroids for Alleviating Dyspnea in Terminal Cancer Patients: A Retrospective Review.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Analgesics, Opioid; Dose-Response Relationship, Dr | 2016 |
Nebulized Fentanyl for Dyspnea in a Hospice Patient with True Allergy to Morphine and Hydromorphone.
Topics: Administration, Inhalation; Aged, 80 and over; Drug Hypersensitivity; Dyspnea; Female; Fentanyl; Hos | 2017 |
Pharmacologic intervention for cancer-related dyspnea.
Topics: Analgesics, Opioid; Chlorpromazine; Dyspnea; Fentanyl; Humans; Neoplasms; Palliative Care; Randomize | 2008 |
Intranasal fentanyl for episodic breathlessness.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Analgesics, Opioid; Dyspnea; Female; Fentanyl; | 2008 |
Anesthesia case of the month.
Topics: Anesthesia, General; Anesthetics, Intravenous; Animals; Cat Diseases; Cats; Dyspnea; Endoscopy, Gast | 2009 |
[Successful management of a patient with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for non-small cell lung cancer (NSCLC) in whom optimal dosages of transdermal fentanyl were determined by titration with fentanyl i
Topics: Administration, Cutaneous; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Dyspnea; Female; Fentanyl | 2010 |
[Home hospice care for the lung cancer patients].
Topics: Analgesics, Opioid; Dyspnea; Fentanyl; Home Care Services; Hospice Care; Humans; Lung Neoplasms; Mor | 2009 |
The safety of flexible fibre-optic bronchoscopy and proceduralist-administered sedation: a tertiary referral centre experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Bronchoscopy; Conscious Sedation; Dyspnea; Femal | 2012 |
Ketamine for palliative sedation in the emergency department.
Topics: Advance Directive Adherence; Aged, 80 and over; Airway Obstruction; Anesthetics, Dissociative; Anest | 2013 |
[Anaestheia for valve replacement in the second trimester of pregnancy].
Topics: Acute Disease; Adult; Anesthesia, General; Cardiotocography; Chorea Gravidarum; Dyspnea; Emergencies | 2014 |
[Anesthesia in a patient with acute strangulation of a massive diaphragmatic hernia].
Topics: Adjuvants, Anesthesia; Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, Combined | 2003 |
[Anesthetic management for a patient with platypnea-orthodeoxia syndrome].
Topics: Aged; Anesthesia, General; Dyspnea; Fentanyl; Heart Septal Defects, Atrial; Humans; Hypoxia; Male; M | 2004 |
Nebulized fentanyl provides subjective improvements for patients with dyspnea.
Topics: Administration, Inhalation; Dyspnea; Fentanyl; Humans; Lung Neoplasms; Narcotics; Nebulizers and Vap | 2005 |
[Appropriate dose of isobaric bupivacaine with fentanyl in spinal anesthesia for cesarean section].
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Anesthetics, Combined; Ane | 2005 |
Oral transmucosal fentanyl citrate in the management of dyspnea crises in cancer patients.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Dyspnea; Female; Fentanyl; Humans; Lung Neoplasms; M | 2005 |
Fentanyl may increase breathlessness in a patient with motor neuron disease.
Topics: Aged; Anesthetics, Intravenous; Dyspnea; Female; Fentanyl; Humans; Motor Neuron Disease; Neck Pain; | 2006 |
Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Dyspnea; Female; Fentanyl; Heart Failure; Humans; Lung | 2008 |
Fentanyl for dyspnea relief.
Topics: Acute Disease; Administration, Inhalation; Analgesics, Opioid; Dyspnea; Fentanyl; Humans | 1998 |
[Subarachnoid anesthesia in the repair of urinary stress incontinence using a Burch-type colposuspension by means of extraperitoneal laparoscopy].
Topics: Adult; Aged; Anesthesia, General; Anesthesia, Spinal; Bupivacaine; Carbon Dioxide; Chest Pain; Dyspn | 2002 |